Essential Premium

Biopharma Specialist Cormorant Plans New $125 Million Blank-Check Venture

As Cormorant makes plans for another Special Purpose Acquisition Company, here’s how the firm’s previous SPACs have fared.

Hedge Funds Hope to Cash In on Perceptive Advisors’ SPAC

Biopharma hedge funds have lined up for stakes in a recent merger involving a blank-check company.

Sponsored

From Chaos to Clarity: Solving Your Daily Data Challenges

Marc Rubinstein on the Hidden Fault Lines in Modern Finance

The former Lansdowne partner and portfolio manager dishes on private equity and credit, PE-owned insurance, and multimanager hedge funds.

Related Content

Bucking the Trend, Top Hedge Fund Makes Plans for a Second SPAC

Stephen Taub

Is the SPAC Comeback for Real?

Michelle Celarier

As New SPAC Rules Go Into Effect, the Numbers Show a Tepid Comeback

Michelle Celarier

1270 Avenue of the Americas, Suite 1100

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site. Institutional Investor is part of Delinian.

 

| Unsubscribe

LinkedIn
X (Twitter)
Bluesky
Instagram